The Impact Of The Neonatal Gut Microbiome On Specific And Nonspecific Vaccine Responses.
Funder
National Health and Medical Research Council
Funding Amount
$661,496.00
Summary
Humans are colonised by a large and diverse group of microorganisms, collectively known as the microbiome. The gut microbiome, in particular, hosts an enormous abundance and diversity of bacteria, which perform a range of essential beneficial functions. Our study will investigate whether disruption of the gut microbiome in newborns, for example through antibiotic usage or maternal diet, leads to an impairment of subsequent immune responses to childhood immunisations.
Multistage Vaccines For The Prevention Of Tuberculosis
Funder
National Health and Medical Research Council
Funding Amount
$884,290.00
Summary
Almost two million people die from tuberculosis (TB) each year. The current vaccine, BCG, is ineffective at controlling TB and the type of immune response needed to protect against the disease is poorly understood. We have discovered new antigens of the TB bacterium, and we will combine them with novel delivery strategies to develop new TB vaccines. We will also determine the type of immune response needed to protect against TB, which will aid progression of vaccines into clinical trials.
A Randomised Controlled Trial (RCT) Of Azithromycin Versus Doxycycline For The Treatment Of Rectal Chlamydia Infection In Men Who Have Sex With Men.
Funder
National Health and Medical Research Council
Funding Amount
$797,906.00
Summary
Rectal chlamydia is very common among gay men; it can exist for long periods without symptoms leading to ongoing transmission. Azithromycin (1 gram single dose) or 7 days doxycycline (100mg twice daily) are the two recommended treatments globally. But, there is concern about rectal chlamydia treatment with reports of up to 22% failure following azithromycin. We will conduct a randomised trial to compare these treatments for rectal chlamydia and determine which drug works better.
Probiotic Prawn Oral Immunotherapy (ProPIT) For Treatment Of Prawn Allergy
Funder
National Health and Medical Research Council
Funding Amount
$1,865,369.00
Summary
A ‘curative’ food allergy treatment is needed to prevent deaths and improve care. We recently showed that probiotic peanut oral immunotherapy (PPOIT) was highly effective for treating peanut allergy. 82% of PPOIT treated children gained tolerance compared to 4% of the placebo group. We will now test the combined probiotic-food OIT approach for treating prawn allergy. If successful, we will have identified the first treatment for prawn allergy and a platform treatment for other food allergies.
An In Depth Analysis Of Clinical And Virological Outcomes Of 2 Strategies For The Antiretroviral Salvage Of First-line Regimen Virological Failure For HIV-1 Infection Tested In An Australian-led Randomised, International, Multi-centre Clinical Trial
Funder
National Health and Medical Research Council
Funding Amount
$421,747.00
Summary
The recently completed Australian-led SECOND-LINE trial is the first high quality study to provide reliable evidence for policy recommendations for the composition of anti-HIV drug cocktails after standard initial treatment has failed. This award will support the researcher in further refining our understanding of how to manage second-line therapy including proposals to test the use of low-cost technologies for application in resource-limited settings where the majority of people with HIV live.
Early Career Industry Fellowships - Grant ID: IE230100437
Funder
Australian Research Council
Funding Amount
$417,237.00
Summary
Nanobubbles for effective and energy efficient water treatment. This project aims to produce new knowledge for developing ozone nanobubbles as a technological option for the water industry where commercially suitable technologies are unavailable. Australian water utilities have identified two key challenges: destruction of micropollutants and natural organic matter in recycled and reservoir water, respectively. New knowledge from the project will allow these water utilities to utilise the extrao ....Nanobubbles for effective and energy efficient water treatment. This project aims to produce new knowledge for developing ozone nanobubbles as a technological option for the water industry where commercially suitable technologies are unavailable. Australian water utilities have identified two key challenges: destruction of micropollutants and natural organic matter in recycled and reservoir water, respectively. New knowledge from the project will allow these water utilities to utilise the extraordinary properties of nanobubbles and the strong oxidation capability of ozone for effective and energy efficient water treatment. Tech-transfer to the industry is guaranteed through a scientifically designed pilot plant for benchmarking against the current state of the art ozonation process and reverse osmosis.Read moreRead less
Uptake, Sustainability And Impact Of Scaling Up Point-of-care Testing For Sexually Transmissible Infections In Remote And Regional Aboriginal Communities
Funder
National Health and Medical Research Council
Funding Amount
$1,461,788.00
Summary
Aboriginal youth experience unacceptably high rates of curable sexually transmissible infections (STI). Coverage of testing and treatment is insufficient for disease control but could be enhanced via point-of-care (POC) testing. We have been trialling a highly accurate STI/POC diagnostic in the TTANGO (Test, Treat ANd GO) trial. The TTANGO2 partnership will assess the long-term uptake, sustainability and impact of POC testing in 20 Aboriginal health services in regional/remote WA over 5 years.
Pathophysiology And Alternative Preventative Strategy For Breast Cancer Chemotherapy-induced Bone Loss
Funder
National Health and Medical Research Council
Funding Amount
$540,356.00
Summary
Combination cytotoxic chemotherapy is the current optimal approach for treating breast cancer in premenopausal women. However, long-term skeletal defects (osteoporosis and fractures) caused by the chemotherapy have become an increasingly serious problem due to its intensified use and improved patient survival rate. This project seeks to elucidate the mechanisms for chemotherapy-induced bone defects and to initiate development of a preventative treatment using natural bioactive micronutrients.
Early stress experiences and stress resilience in pigs. Animal stress has substantial implications on animal productivity, health and welfare of farm animals and thus farm profitability. This project aims to examine the stress resilience in pigs. Modern pig farming is a major source of food, providing substantial nutritional, social and economic benefits in Australia and worldwide. Animal welfare is of increasing concern to the public, consumers and pork producers, and stress vulnerability is an ....Early stress experiences and stress resilience in pigs. Animal stress has substantial implications on animal productivity, health and welfare of farm animals and thus farm profitability. This project aims to examine the stress resilience in pigs. Modern pig farming is a major source of food, providing substantial nutritional, social and economic benefits in Australia and worldwide. Animal welfare is of increasing concern to the public, consumers and pork producers, and stress vulnerability is an animal health and production problem in the life of the commercial pig. This project will generate new knowledge on early life management to endow stress resilience in pigs, with expected benefits for animal welfare, farm productivity and profitability.Read moreRead less
Preclinical Evaluation Of The Novel Therapeutic Compound APP96-110 In An Ovine Model Of Traumatic Brain Injury
Funder
National Health and Medical Research Council
Funding Amount
$874,734.00
Summary
Traumatic brain injury (TBI) is a significant cause of death and disability, and yet there are currently no effective treatments to improve outcome following such an insult. Our laboratory has developed a novel therapeutic compound, by identifying an endogenous neuroprotective molecule, in the amyloid precursor protein and then identifying the active site and modifying it to improve its efficacy. We will be testing this compound in our sheep model of TBI.